StreetInsider.com News Articles

China Pharma Holdings closes $5M direct offering at $2 per share

Thu, 23 Jul 2026 18:50:41 -0400

China Pharma Holdings, Inc. (NYSE American: CPHI) announced the closing of a registered direct offering of 2,500,000 shares of common stock at $2.00 per share, generating $5 million in gross proceeds before placement agent fees and other expenses.

The offering closed on July 23, 2026. The company said it intends to use the net proceeds for working capital and general corporate purposes.

FT Global Capital, Inc. served as the exclusive placement agent for the offering.

The offering was made under the company's shelf registration statement on Form S-3, initially filed with the U.S. Securities and Exchange Commission on January 12, 2024, and declared

China Pharma Holdings closes $5M direct offering at $2 per share

Thu, 23 Jul 2026 18:50:41 -0400

The offering closed on July 23, 2026. The company said it intends to use the net proceeds for working capital and general corporate purposes.

FT Global Capital, Inc. served as the exclusive placement agent for the offering.

The offering was made under the company's shelf registration statement on Form S-3, initially filed with the U.S. Securities and Exchange Commission on January 12, 2024, and declared

China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering

Thu, 23 Jul 2026 18:49:00 -0400

HAIKOU, China, July 23, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) (the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced the closing of its previously announced registered direct offering of 2,500,000 shares of the Company's common stock, par value $0.001 per share, at a purchase price of $2.00 per share. The gross proceeds from the offering are $5 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from this offering for working capital and

China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering

Thu, 23 Jul 2026 18:49:00 -0400

China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering

Thu, 23 Jul 2026 18:49:00 -0400

China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering

Thu, 23 Jul 2026 18:49:00 -0400

Form 424B5 CHINA PHARMA HOLDINGS,

Thu, 23 Jul 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260723/26803941.html

Form 424B5 CHINA PHARMA HOLDINGS,

Thu, 23 Jul 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260723/26803941.html

Form 8-K CHINA PHARMA HOLDINGS, For: Jul 22

Wed, 22 Jul 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260722/26802756.html

Form 8-K CHINA PHARMA HOLDINGS, For: Jul 22

Wed, 22 Jul 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260722/26802756.html

China Pharma prices $5 million direct offering at $2 per share

Wed, 22 Jul 2026 09:25:08 -0400

China Pharma Holdings, Inc. (NYSE American: CPHI) announced the pricing of a registered direct offering of 2.5 million shares of common stock at $2 per share, according to a press release.

The offering is expected to generate $5 million in gross proceeds before placement agent fees and other expenses. The company said it plans to use the net proceeds for working capital and general corporate purposes.

The offering was expected to close on or about July 23, 2026. FT Global Capital, Inc. is acting as the exclusive placement agent.

The offering was made under the company's shelf registration statement on Form F-3, filed

China Pharma prices $5 million direct offering at $2 per share

Wed, 22 Jul 2026 09:25:08 -0400

China Pharma Holdings, Inc. (NYSE American: CPHI) announced the pricing of a registered direct offering of 2.5 million shares of common stock at $2 per share, according to a press release.

The offering was expected to close on or about July 23, 2026. FT Global Capital, Inc. is acting as the exclusive placement agent.

The offering was made under the company's shelf registration statement on Form F-3, filed

China Pharma Announces Pricing of $5 Million Registered Direct Offering

Wed, 22 Jul 2026 09:25:00 -0400

HAIKOU, China, July 22, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that the pricing of its registered direct offering of 2.5 million shares of its common stock ("Common Shares"), at a purchase price of $2 per share.

The gross proceeds from the offering will be $5 million, before deducting placement agent fees and other offering expenses.

The Company intends to use the net proceeds from this offering for working capital

China Pharma Announces Pricing of $5 Million Registered Direct Offering

Wed, 22 Jul 2026 09:25:00 -0400

The gross proceeds from the offering will be $5 million, before deducting placement agent fees and other offering expenses.

The Company intends to use the net proceeds from this offering for working capital

China Pharma Announces Pricing of $5 Million Registered Direct Offering

Wed, 22 Jul 2026 09:25:00 -0400

The gross proceeds from the offering will be $5 million, before deducting placement agent fees and other offering expenses.

The Company intends to use the net proceeds from this offering for working capital

China Pharma Announces Pricing of $5 Million Registered Direct Offering

Wed, 22 Jul 2026 09:25:00 -0400

The gross proceeds from the offering will be $5 million, before deducting placement agent fees and other offering expenses.

The Company intends to use the net proceeds from this offering for working capital

China Pharma says it knows of no reason for unusual stock activity

Tue, 21 Jul 2026 16:01:23 -0400

China Pharma Holdings, Inc. (NYSE American: CPHI) stated it is unaware of any material corporate developments that would explain unusual trading activity in its common stock on July 21, 2026.

The NYSE American contacted the company in connection with the activity, consistent with its standard practice. China Pharma issued its statement under Section 401(d) of the NYSE American Company Guide.

The company cautioned shareholders and prospective investors to exercise care when evaluating its securities given the recent volatility, and to rely only on information contained in its filings with the U.S. Securities and Exchange Commission and its official press releases.

China Pharma says it knows of no reason for unusual stock activity

Tue, 21 Jul 2026 16:01:23 -0400

China Pharma Holdings, Inc. (NYSE American: CPHI) stated it is unaware of any material corporate developments that would explain unusual trading activity in its common stock on July 21, 2026.

China Pharma Holdings, Inc. Comments on Unusual Market Activity

Tue, 21 Jul 2026 16:00:00 -0400

HAIKOU, China, July 21, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 21, 2026, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it issued this statement under Section 401(d) of the NYSE

China Pharma Holdings, Inc. Comments on Unusual Market Activity

Tue, 21 Jul 2026 16:00:00 -0400

China Pharma Holdings, Inc. Comments on Unusual Market Activity

Tue, 21 Jul 2026 16:00:00 -0400

China Pharma Holdings, Inc. Comments on Unusual Market Activity

Tue, 21 Jul 2026 16:00:00 -0400

China Pharma says it has no explanation for unusual stock activity

Wed, 15 Jul 2026 12:41:24 -0400

China Pharma Holdings, Inc. (NYSE American: CPHI) said it is unaware of any material nonpublic information or undisclosed business developments that would explain unusual trading activity in its common stock on July 10, 13, and 15, 2026.

The company, based in Haikou, China, said NYSE American contacted it in accordance with standard exchange practice following the unusual market activity. China Pharma noted that its general policy is not to comment on such activity but issued the statement in response to the exchange's inquiry.

China Pharma says it has no explanation for unusual stock activity

Wed, 15 Jul 2026 12:41:24 -0400

China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity

Wed, 15 Jul 2026 12:12:00 -0400

HAIKOU, China, July 15, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 10, 13, and 15, 2026, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it is not aware of any material